Home
CMPX
CMPX News

Latest Compass Therapeutics Inc. (CMPX) News on January 19, 2025

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

GlobeNewswire

11 days ago

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate

US Penny Stocks To Watch In January 2025

Simply Wall St.

12 days ago

US Penny Stocks To Watch In January 2025

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

GlobeNewswire

a month ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Top US Penny Stocks To Watch In December 2024

Simply Wall St.

2 months ago

Top US Penny Stocks To Watch In December 2024

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

2 months ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire

2 months ago

Compass Therapeutics to Participate in Upcoming Investor Events

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire

2 months ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire

2 months ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M

Simply Wall St.

2 months ago

US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire

3 months ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Compass Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire

5 months ago

Compass Therapeutics to Participate in Upcoming Investor Events

Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Simply Wall St.

5 months ago

Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

GlobeNewswire

5 months ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer

GlobeNewswire

5 months ago

Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer

Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation

Simply Wall St.

6 months ago

Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

GlobeNewswire

8 months ago

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

Compass Therapeutics Announces CEO Transition

GlobeNewswire

8 months ago

Compass Therapeutics Announces CEO Transition

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

GlobeNewswire

8 months ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire

8 months ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

GlobeNewswire

8 months ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

GlobeNewswire

9 months ago

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

GlobeNewswire

9 months ago

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

GlobeNewswire

9 months ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

GlobeNewswire

9 months ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

9 months ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

GlobeNewswire

10 months ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire

a year ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

GlobeNewswire

a year ago

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Rekor Discover(TM) Broadens Reach in Western U.S. with New Expansion

ACCESSWIRE

a year ago

Rekor Discover(TM) Broadens Reach in Western U.S. with New Expansion

Middlefield Banc Corp. Reports 2023 Full-Year Financial Results

GlobeNewswire

a year ago

Middlefield Banc Corp. Reports 2023 Full-Year Financial Results

Porch Group Receives $25M with Signing of Strategic Agreement with Aon

Business Wire

a year ago

Porch Group Receives $25M with Signing of Strategic Agreement with Aon

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

GlobeNewswire

a year ago

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Are Investors Undervaluing Edgewell Personal Care (EPC) Right Now?

Zacks

a year ago

Are Investors Undervaluing Edgewell Personal Care (EPC) Right Now?

Business Wire

a year ago

Manitowoc Board of Directors Elects Ryan M. Gwillim as New Director

Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?

Zacks

a year ago

Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?

The Manitowoc Company, Inc. (MTW) Stock Dips While Market Gains: Key Facts

Zacks

a year ago

The Manitowoc Company, Inc. (MTW) Stock Dips While Market Gains: Key Facts

Groupon, Inc. Provides Business Update

Newsfile

a year ago

Groupon, Inc. Provides Business Update

Euroseas Ltd. Announces Time Charter Contract for its Fuel-Efficient 2,800 teu Feeder Containership, M/V Tender Soul, to be delivered in February 2024

GlobeNewswire

a year ago

Euroseas Ltd. Announces Time Charter Contract for its Fuel-Efficient 2,800 teu Feeder Containership, M/V Tender Soul, to be delivered in February 2024

The Zacks Analyst Blog Highlights Amazon.com, Wayfair, Rover Group, Groupon and 1stdibs.Com

Zacks

a year ago

The Zacks Analyst Blog Highlights Amazon.com, Wayfair, Rover Group, Groupon and 1stdibs.Com

Codorus Valley Bancorp, Inc. Declares Quarterly Cash Dividend

GlobeNewswire

a year ago

Codorus Valley Bancorp, Inc. Declares Quarterly Cash Dividend

5 Online Retailers to Buy Despite Weak Holiday Retail Sales

Zacks

a year ago

5 Online Retailers to Buy Despite Weak Holiday Retail Sales

DocGo Subsidiary Achieves ISO 9001:2015 Certification, Further Elevating its Commitment to Quality Management

Business Wire

a year ago

DocGo Subsidiary Achieves ISO 9001:2015 Certification, Further Elevating its Commitment to Quality Management

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

GlobeNewswire

a year ago

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights

Here's Why You Should Retain Accuray (ARAY) Stock for Now

Zacks

a year ago

Here's Why You Should Retain Accuray (ARAY) Stock for Now

RETRANSMISSION: HIVE Digital Provides Recap of Calendar Year 2023 Mining 3,260 Bitcoin

Newsfile

a year ago

RETRANSMISSION: HIVE Digital Provides Recap of Calendar Year 2023 Mining 3,260 Bitcoin

Compass Therapeutics Provides Corporate Update

GlobeNewswire

a year ago

Compass Therapeutics Provides Corporate Update

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire

a year ago

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a year ago

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

7 Short-Squeeze Stocks That Are Screaming for Speculation

InvestorPlace

a year ago

7 Short-Squeeze Stocks That Are Screaming for Speculation

Alaska Air Group (ALK) Fell on Weak Airline Price

Insider Monkey

a year ago

Alaska Air Group (ALK) Fell on Weak Airline Price

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

GlobeNewswire

a year ago

Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing

GlobeNewswire

a year ago

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing

Arteris Inc CFO Nicholas Hawkins Sells 20,000 Shares: An Insider Sell Analysis

GuruFocus.com

a year ago

Arteris Inc CFO Nicholas Hawkins Sells 20,000 Shares: An Insider Sell Analysis

Compass Therapeutics Insider Ups Holding During Year

Simply Wall St.

a year ago

Compass Therapeutics Insider Ups Holding During Year

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

PR Newswire

a year ago

KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB®

Zacks Small Cap Research

a year ago

KMDA: Amendment and Extension of Kedrab® U.S. Distribution Agreement to Generate at Least $180 Million Over First Four Years…

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

GlobeNewswire

a year ago

Kamada Announces its Largest Commercial Agreement; A Strategic Engagement with Kedrion for U.S. Distribution of KEDRAB® including $180 Million of Revenues Over First Four Years

Atlas Lithium Fully Funded to First Production in 2024

Newsfile

a year ago

Atlas Lithium Fully Funded to First Production in 2024

Capital City Bank Named Among “Best Banks to Work For” By American Banker For 11 Years In A Row

GlobeNewswire

a year ago

Capital City Bank Named Among “Best Banks to Work For” By American Banker For 11 Years In A Row

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Business Wire

a year ago

Harrow Completes Transfer of the TRIESENCE® New Drug Application

Harrow to Present at Two Investor Conferences in November

Business Wire

a year ago

Harrow to Present at Two Investor Conferences in November

Great week for SoundThinking, Inc. (NASDAQ:SSTI) institutional investors after losing 30% over the previous year

Simply Wall St.

a year ago

Great week for SoundThinking, Inc. (NASDAQ:SSTI) institutional investors after losing 30% over the previous year

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

Zacks Small Cap Research

a year ago

KMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…

BRT Apartments Corp. (NYSE:BRT) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

BRT Apartments Corp. (NYSE:BRT) Q3 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

a year ago

Q3 2023 WhiteHorse Finance Inc Earnings Call

GuruFocus.com

a year ago

Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments

GuruFocus.com

a year ago

WhiteHorse Finance Inc Reports Q3 Earnings and Declares Increased Dividend

Associated Press Finance

a year ago

WhiteHorse: Q3 Earnings Snapshot

WhiteHorse Finance, Inc. Announces Third Quarter 2023 Earnings Results and Declares Increased Quarterly Distribution to $0.385 Per Share

PR Newswire

a year ago

WhiteHorse Finance, Inc. Announces Third Quarter 2023 Earnings Results and Declares Increased Quarterly Distribution to $0.385 Per Share

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NextNav Inc. Reports Third Quarter 2023 Results

GlobeNewswire

a year ago

NextNav Inc. Reports Third Quarter 2023 Results

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2023 Earnings Call Transcript

Atlas Lithium Secures US$ 20,000,000 Investment from Lithium Investors Including Lead Advisor Martin Rowley

Newsfile

a year ago

Atlas Lithium Secures US$ 20,000,000 Investment from Lithium Investors Including Lead Advisor Martin Rowley

Thomson Reuters StreetEvents

a year ago

Q3 2023 BRT Apartments Corp Earnings Call

Compass Therapeutics to Participate in Upcoming Investor Events

GlobeNewswire

a year ago

Compass Therapeutics to Participate in Upcoming Investor Events

Associated Press Finance

a year ago

BRT: Q3 Earnings Snapshot

GuruFocus.com

a year ago

BRT Apartments Corp (BRT) Reports Q3 2023 Earnings, Affirms Full Year Guidance

BRT Apartments Corp. Reports Third Quarter 2023 Results

GlobeNewswire

a year ago

BRT Apartments Corp. Reports Third Quarter 2023 Results

CSI Compressco LP (CCLP) Announces Q3 2023 Results: 14% YoY Quarterly Adjusted EBITDA Growth

GuruFocus.com

a year ago

CSI Compressco LP (CCLP) Announces Q3 2023 Results: 14% YoY Quarterly Adjusted EBITDA Growth

Associated Press Finance

a year ago

CSI Compressco: Q3 Earnings Snapshot

CSI COMPRESSCO LP ANNOUNCES THIRD QUARTER 2023 RESULTS; ACHIEVES 14% YEAR-ON-YEAR QUARTERLY ADJUSTED EBITDA GROWTH; CONTINUES LEVERAGE REDUCTION

PR Newswire

a year ago

CSI COMPRESSCO LP ANNOUNCES THIRD QUARTER 2023 RESULTS; ACHIEVES 14% YEAR-ON-YEAR QUARTERLY ADJUSTED EBITDA GROWTH; CONTINUES LEVERAGE REDUCTION

Share on Social Networks: